BWX Technologies Free cash flow decreased by 11.8% to $50.09M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 189.9%, from $17.28M to $50.09M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a 40.9% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$8.33M | $769.00K | $86.05M | -$57.80M | $34.89M | $25.35M | $43.95M | -$42.80M | $40.81M | $43.43M | $170.98M | $2.60M | $35.49M | $0.00 | $224.36M | $17.28M | $126.31M | $94.89M | $56.80M | $50.09M |
| QoQ Change | — | +109.2% | >999% | -167.2% | +160.4% | -27.3% | +73.4% | -197.4% | +195.3% | +6.4% | +293.7% | -98.5% | >999% | -100.0% | — | -92.3% | +630.9% | -24.9% | -40.1% | -11.8% |
| YoY Change | — | — | — | — | +518.9% | >999% | -48.9% | +25.9% | +17.0% | +71.3% | +289.0% | +106.1% | -13.0% | -100.0% | +31.2% | +563.6% | +255.9% | — | -74.7% | +189.9% |